There are also several reports presenting how ddPCR assays allow for PD-L1 quantification in CTCs [191]; notably, the expression of PD-L1 on CTCs has been shown to predict the response to pembrolizumab in advanced melanoma patients [231]. This evidence concerns the gene CD274 and melanoma.